Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
948 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03874858 | A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia(DANTE) | terminated | Phase 2 | 135 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06517719 | Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer | recruiting | — | 500 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 13, 2026 |
| clinicaltrials |
| NCT07243002 | Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.(REPOWER) | recruiting | — | 3,000 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT03439046 | Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant(BioItaLEE) | terminated | Phase 3 | 287 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06004661 | Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function | active not recruiting | Phase 2 | 23 | Novartis PharmaceuticalsINDUSTRY | 5 | Jul 10, 2026 | clinicaltrials |
| NCT03114319 | Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 227 | Novartis PharmaceuticalsINDUSTRY | 9 | Jul 9, 2026 | clinicaltrials |
| NCT03568461 | Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma(ELARA) | completed | Phase 2 | 98 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 9, 2026 | clinicaltrials |
| NCT03591510 | A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML | active not recruiting | Phase 2 | 22 | Novartis PharmaceuticalsINDUSTRY | 10 | Jul 9, 2026 | clinicaltrials |
| NCT04318327 | BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma | terminated | Phase 1 | 96 | Novartis PharmaceuticalsINDUSTRY | 4 | Jul 9, 2026 | clinicaltrials |
| NCT05631795 | Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment(ALPINIST) | completed | Phase 4 | 40 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06376253 | A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers | terminated | Phase 1 | 4 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT03671330 | Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. | completed | Phase 2 | 327 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04877522 | Asciminib Roll-over Study | recruiting | Phase 4 | 347 | Novartis PharmaceuticalsINDUSTRY | 29 | Jul 6, 2026 | clinicaltrials |
| NCT06514521 | Post Marketing Study on Pluvicto in Korea | recruiting | — | 278 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06797531 | RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia(NISLEESA) | recruiting | — | 177 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07635316 | A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients | recruiting | — | 4,023 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04857372 | A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors | active not recruiting | Phase 1 | 137 | Novartis PharmaceuticalsINDUSTRY | 11 | Jun 22, 2026 | clinicaltrials |
| NCT07570966 | Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Jun 22, 2026 | clinicaltrials |
| NCT03631199 | Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects(CANOPY-1) | terminated | Phase 3 | 673 | Novartis PharmaceuticalsINDUSTRY | 41 | Jun 17, 2026 | clinicaltrials |
| NCT05293470 | A Post Marketing Surveillance on Piqray in Korea | recruiting | — | 900 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT06262919 | Special Drug Use-results Surveillance of Tafinlar/Mekinist | recruiting | — | 110 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07261631 | Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors | recruiting | Phase 1 | 180 | Novartis PharmaceuticalsINDUSTRY | 6 | Jun 17, 2026 | clinicaltrials |
| NCT07649252 | A Study of Patient Characteristics and Treatment Patterns in Real-world Melanoma Patients Treated With Dabrafenib and Trametinib or Encorafenib and Binimetinib in Japan | completed | — | 82 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07653126 | A Study of Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in Germany(LUNET-2) | completed | — | 117 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05358249 | Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation(KontRASt-03) | active not recruiting | Phase 1 / Phase 2 | 74 | Novartis PharmaceuticalsINDUSTRY | 8 | Jun 15, 2026 | clinicaltrials |
| NCT07647042 | A Real-World Study of Early Breast Cancer Patients Eligible for Treatment With CDK4/6 Inhibitors(LEEWARD) | completed | — | 750 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT03570892 | Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma(BELINDA) | completed | Phase 3 | 330 | Novartis PharmaceuticalsINDUSTRY | 18 | Jun 12, 2026 | clinicaltrials |
| NCT07644351 | A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients(ASCERTAIN) | completed | — | 37 | Novartis PharmaceuticalsINDUSTRY | 12 | Jun 12, 2026 | clinicaltrials |
| NCT06401356 | An Extension Study for Patients Previously Enrolled in Studies With Pelabresib | recruiting | Phase 3 | 50 | Novartis PharmaceuticalsINDUSTRY | 5 | Jun 11, 2026 | clinicaltrials |
| NCT07378969 | A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy(Lythesia) | recruiting | — | 30 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04720157 | An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)(PSMAddition) | active not recruiting | Phase 3 | 1,140 | Novartis PharmaceuticalsINDUSTRY | 19 | Jun 8, 2026 | clinicaltrials |
| NCT06427811 | Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation(ASC4INDIA) | completed | Phase 4 | 85 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT03960840 | Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL | active not recruiting | Phase 1 / Phase 2 | 217 | Novartis PharmaceuticalsINDUSTRY | 8 | Jun 4, 2026 | clinicaltrials |
| NCT04729387 | Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected | terminated | Phase 3 | 358 | Novartis PharmaceuticalsINDUSTRY | 26 | Jun 4, 2026 | clinicaltrials |
| NCT05803941 | Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer | recruiting | Phase 4 | 700 | Novartis PharmaceuticalsINDUSTRY | 11 | Jun 4, 2026 | clinicaltrials |
| NCT05703516 | A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea | recruiting | — | 44 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06092879 | Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France(ASSURE-3) | active not recruiting | — | 201 | Novartis PharmaceuticalsINDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT07093801 | Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer | recruiting | — | 300 | Novartis PharmaceuticalsINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT05114746 | Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan | completed | Phase 2 | 94 | Novartis PharmaceuticalsINDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT05155709 | A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. | completed | Phase 1 | 14 | Novartis PharmaceuticalsINDUSTRY | 7 | May 7, 2026 | clinicaltrials |
| NCT06905301 | Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice(IMPULSE) | recruiting | — | 240 | Novartis PharmaceuticalsINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT04727723 | Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs(REAL-LU) | completed | — | 164 | Novartis PharmaceuticalsINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT03601442 | Managed Access Programs for CTL019, Tisagenlecleucel | available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 23, 2026 | clinicaltrials |
| NCT01682083 | Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).(COMBI-AD) | completed | Phase 3 | 870 | Novartis PharmaceuticalsINDUSTRY | 25 | Apr 21, 2026 | clinicaltrials |
| NCT03578367 | Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response. | completed | Phase 2 | 104 | Novartis PharmaceuticalsINDUSTRY | 15 | Apr 21, 2026 | clinicaltrials |
| NCT06514534 | Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.(ASC4TARGET) | recruiting | Phase 2 | 20 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05943522 | Asciminib RMP Study | recruiting | — | 600 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05888493 | A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma(LEDA) | active not recruiting | Phase 3 | 109 | Novartis PharmaceuticalsINDUSTRY | 11 | Apr 17, 2026 | clinicaltrials |
| NCT02934568 | Ribociclib (LEE011) Rollover Study for Continued Access | active not recruiting | Phase 2 | 22 | Novartis PharmaceuticalsINDUSTRY | 6 | Apr 16, 2026 | clinicaltrials |
| NCT04085653 | Managed Access Programs for BYL719, Alpelisib | available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 14, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials